Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag for refractory or relapsed severe aplastic anaemia
ACTRN12619001043123Phase 2Active, not recruiting
- Sponsor
- Monash University
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avatrombopag in aplastic anemia and severe aplastic anemia (SAA), sponsored by Monash University. Primary endpoints: Overall haematological response rate and Acquired clonal evolution. Started Oct 2019; status: active, not recruiting.
02
Drugs
avatrombopag
03
Conditions
aplastic anemiasevere aplastic anemia (SAA)
Beyond the preview
Go deeper on ACTRN12619001043123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001043123.